Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Filipović, SR; Özturk, S; Bereczki, D; Bodini, B; Cavallieri, F; Fanciulli, A; Guekht, A; Helbok, R; Hochmeister, S; Martinelli, Boneschi, F; Priori, A; Rakusa, M; Romoli, M; Willekens, B; Zedde, M; Sellner, J; Moro, E, , Neuro, COVID‐19, Task, Force, of, the, European, Academy, of, Neurology.
Management of patients with neurological diseases considering post-pandemic coronavirus disease 2019 (COVID-19) related risks and dangers - An updated European Academy of Neurology consensus statement.
Eur J Neurol. 2024; 31(10):e16408
Doi: 10.1111/ene.16408
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Hochmeister Sonja
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND AND PURPOSE: In October 2020, the European Academy of Neurology (EAN) consensus statement for management of patients with neurological diseases during the coronavirus disease 2019 (COVID-19) pandemic was published. Due to important changes and developments that have happened since then, the need has arisen to critically reassess the original recommendations and address new challenges. METHODS: In step 1, the original items were critically reviewed by the EAN COVID-19 Task Force. In addition, new recommendations were defined. In step 2, an online survey with the recommendations forged in step 1 was sent to the Managing Groups of all Scientific and Coordinating Panels of EAN. In step 3, the final set of recommendations was made. RESULTS: In step 1, out of the original 36 recommendations, 18 were judged still relevant. They were edited to reflect the advances in knowledge and practice. In addition, 21 new recommendations were formulated to address the new knowledge and challenges. In step 2, out of the 39 recommendations sent for the survey, nine were approved as they were, whilst suggestions for improvement were given for the rest. In step 3, the recommendations were further edited, and some new items were formed to accommodate the participants' suggestions, resulting in a final set of 41 recommendations. CONCLUSION: This revision of the 2020 EAN Statement provides updated comprehensive and structured guidance on good clinical practice in people with neurological disease faced with SARS-CoV-2 infection. It now covers the issues from the more recent domains of COVID-19-related care, vaccine complications and post-COVID-19 conditions.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- COVID-19 - prevention & control
- Nervous System Diseases - therapy, etiology
- Pandemics - administration & dosage
- SARS-CoV-2 - administration & dosage
- Neurology - standards
- Consensus - administration & dosage
- Europe - administration & dosage
- Pneumonia, Viral - complications, epidemiology
- Coronavirus Infections - complications, therapy
- Betacoronavirus - administration & dosage
- Find related publications in this database (Keywords)
- COVID-19
- immunomodulatory
- multiple sclerosis
- post-COVID-19 syndrome
- SARS-CoV-2
- vaccine